NASDAQ:ACIU

AC Immune - ACIU Stock Forecast, Price & News

$2.22

+0.03 (+1.37%)

(As of 03/24/2023 08:50 PM ET)

Add

Compare

Today's Range: $2.16
▼
$2.23
50-Day Range: $2.14
▼
$2.49
52-Week Range: $1.68
▼
$4.84

Volume: 86,500 shs
Average Volume: 172,979 shs
Market Capitalization: $185.48 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.00

Institutional Ownership

AC Immune MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 485.6% Upside
$13.00 Price Target
Short Interest: Healthy
0.69% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.26
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.78) to ($0.60) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

551st out of 995 stocks

Pharmaceutical Preparations Industry

259th out of 482 stocks

3.5

Analyst's Opinion

Consensus Rating
AC Immune has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.00, AC Immune has a forecasted upside of 485.6% from its current price of $2.22.
Amount of Analyst Coverage
AC Immune has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.69% of the float of AC Immune has been sold short.
Short Interest Ratio / Days to Cover
AC Immune has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in AC Immune has recently decreased by 2.29%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
AC Immune does not currently pay a dividend.
Dividend Growth
AC Immune does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACIU.

2.9

News and Social Media Coverage

News Sentiment
AC Immune has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for AC Immune this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added AC Immune to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AC Immune insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.60% of the stock of AC Immune is held by insiders.
Percentage Held by Institutions
Only 16.78% of the stock of AC Immune is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for AC Immune are expected to grow in the coming year, from ($0.78) to ($0.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AC Immune is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AC Immune is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AC Immune has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AC Immune (NASDAQ:ACIU) Stock

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Receive ACIU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter.

ACIU Stock News Headlines

March 26, 2023 | americanbankingnews.com

AC Immune (NASDAQ:ACIU) Upgraded by StockNews.com to Hold

March 20, 2023 | finanznachrichten.de

AC Immune SA: AC Immune at AD/PD 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline

March 27, 2023 | Oxford Club (Ad)

My No. 1 dividend stock for a LIFETIME of income.

Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.

March 20, 2023 | markets.businessinsider.com

SVB Securities Sticks to Their Buy Rating for AC Immune SA (ACIU)

March 20, 2023 | finance.yahoo.com

AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline

March 20, 2023 | americanbankingnews.com

HC Wainwright Reaffirms Buy Rating for AC Immune (NASDAQ:ACIU)

March 18, 2023 | uk.investing.com

AC Immune earnings missed by CHF0.56, revenue topped estimates

March 18, 2023 | seekingalpha.com

AC Immune: Dementia-Focused Swiss Biotech With A Sad History Of Failures

March 27, 2023 | Oxford Club (Ad)

My No. 1 dividend stock for a LIFETIME of income.

Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.

March 17, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Paratek Pharmaceuticals (PRTK) and AC Immune SA (ACIU)

March 17, 2023 | americanbankingnews.com

AC Immune (NASDAQ:ACIU) Now Covered by Analysts at StockNews.com

March 16, 2023 | finance.yahoo.com

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update

March 15, 2023 | msn.com

AC Immune Earnings Preview

March 8, 2023 | finance.yahoo.com

AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023

February 7, 2023 | finanznachrichten.de

AC Immune SA: AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

February 7, 2023 | finance.yahoo.com

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

January 26, 2023 | marketwatch.com

AC Immune Shares Up 9% on Alzheimer's Vaccine Trial Data

January 26, 2023 | finance.yahoo.com

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

January 18, 2023 | finanznachrichten.de

AC Immune SA: AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer's Disease

January 18, 2023 | finance.yahoo.com

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease

January 7, 2023 | finance.yahoo.com

AC Immune SA's (NASDAQ:ACIU) largest shareholders are private equity firms with 39% ownership, individual investors own 29%

December 27, 2022 | seekingalpha.com

Why I've Added A Full Position In AC Immune To My Tax Loss Selling Basket

December 6, 2022 | seekingalpha.com

AC Immune Could Reload On Upcoming Readout

November 30, 2022 | finance.yahoo.com

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

November 25, 2022 | finance.yahoo.com

Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

November 23, 2022 | finance.yahoo.com

AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference

October 6, 2022 | benzinga.com

AC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer's Disease and Down Syndrome

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ACIU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter.

ACIU Company Calendar

Last Earnings: 11/08/2021
Today: 3/26/2023
Next Earnings (Estimated): 4/27/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ACIU
CUSIP: N/A
CIK: 1651625
Web: www.acimmune.com
Phone: (121) 345-9121
Fax: 41-21-345-9120
Employees: 137
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $13.00
High Stock Price Forecast: $16.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +485.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.90)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-74,140,000.00
Net Margins: N/A
Pretax Margin: -1,797.91%
Return on Equity: -35.34%
Return on Assets: -32.49%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.16
Quick Ratio: 11.16

Sales & Book Value

Annual Sales: $4.12 million
Price / Sales: 45.02
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.12 per share
Price / Book: 1.05

Miscellaneous

Outstanding Shares: 83,550,000
Free Float: 79,709,000
Market Cap: $185.48 million
Optionable: Not Optionable
Beta: 0.59

Key Executives

Andrea Pfeifer
Chief Executive Officer & Director

Christopher Roberts
Chief Financial Officer & Associate VP-Finance

Oliver Sol
VP & Head-Clinical Development

Piergiorgio Donati
Chief Technical Operations Officer

Marie Kosco-Vilbois
Chief Scientific Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ACIU Stock - Frequently Asked Questions

Should I buy or sell AC Immune stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACIU shares.
View ACIU analyst ratings or view top-rated stocks.
What is AC Immune's stock price forecast for 2023?: 2 Wall Street research analysts have issued twelve-month price targets for AC Immune's stock. Their ACIU share price forecasts range from $10.00 to $16.00. On average, they anticipate the company's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 485.6% from the stock's current price.
View analysts price targets for ACIU or view top-rated stocks among Wall Street analysts.
How have ACIU shares performed in 2023?: AC Immune's stock was trading at $2.04 at the start of the year. Since then, ACIU shares have increased by 8.8% and is now trading at $2.22.
View the best growth stocks for 2023 here.
When is AC Immune's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our ACIU earnings forecast.
How were AC Immune's earnings last quarter?: AC Immune SA (NASDAQ:ACIU) announced its quarterly earnings results on Monday, November, 8th. The company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.03.
What is Andrea Pfeifer's approval rating as AC Immune's CEO?: 3 employees have rated AC Immune Chief Executive Officer Andrea Pfeifer on Glassdoor.com. Andrea Pfeifer has an approval rating of 35% among the company's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of AC Immune own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AC Immune investors own include Sorrento Therapeutics (SRNE), Agenus (AGEN), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Abeona Therapeutics (ABEO), AVEO Pharmaceuticals (AVEO), Catalyst Pharmaceuticals (CPRX), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and AbbVie (ABBV).

When did AC Immune IPO?: (ACIU) raised $55 million in an initial public offering (IPO) on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.
What is AC Immune's stock symbol?: AC Immune trades on the NASDAQ under the ticker symbol "ACIU."
Who are AC Immune's major shareholders?: AC Immune's stock is owned by many different retail and institutional investors. Top institutional shareholders include Morgan Stanley (2.33%), Platinum Investment Management Ltd. (1.30%), Wells Fargo & Company MN (0.87%), Assenagon Asset Management S.A. (0.71%), Renaissance Technologies LLC (0.48%) and Avidity Partners Management LP (0.39%).
How do I buy shares of AC Immune?: Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is AC Immune's stock price today?: One share of ACIU stock can currently be purchased for approximately $2.22.
How much money does AC Immune make?: AC Immune (NASDAQ:ACIU) has a market capitalization of $185.48 million and generates $4.12 million in revenue each year. The company earns $-74,140,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis.
How many employees does AC Immune have?: The company employs 137 workers across the globe.
How can I contact AC Immune?: AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The official website for the company is www.acimmune.com. The company can be reached via phone at (121) 345-9121, via email at ir@acimmune.com, or via fax at 41-21-345-9120.

This page (NASDAQ:ACIU) was last updated on 3/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AC Immune - ACIU Stock Forecast, Price & News

AC Immune MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AC Immune (NASDAQ:ACIU) Stock

ACIU Stock News Headlines

ACIU Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ACIU Stock - Frequently Asked Questions

Overall MarketRank^™